Summit Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Summit Therapeutics Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, executive compensation, and a stock incentive plan amendment.
NASDAQ
Summit Therapeutics Inc. will hold its 2025 annual meeting of stockholders virtually on June 12, 2025, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.
NASDAQ
Ujwala Mahatme, a Summit Therapeutics board member since July 2020, has resigned effective June 12, 2024, due to increasing professional commitments, and will not stand for re-election at the upcoming Annual Meeting.
NASDAQ
DEF 14A: Summit Therapeutics Inc. Announces Annual Meeting of Stockholders and Proxy Statement Details
Summit Therapeutics Inc. has scheduled its 2024 annual meeting of stockholders for June 14, 2024, to be held virtually, and has released its proxy statement outlining proposals for voting.